Success Metrics

Clinical Success Rate
60.0%

Based on 3 completed trials

Completion Rate
60%(3/5)
Active Trials
5(42%)
Results Posted
33%(1 trials)
Terminated
2(17%)

Phase Distribution

Ph not_applicable
3
25%
Ph phase_1
1
8%
Ph phase_2
3
25%

Phase Distribution

1

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
1(14.3%)
Phase 2Efficacy & side effects
3(42.9%)
N/ANon-phased studies
3(42.9%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

60.0%

3 of 5 finished

Non-Completion Rate

40.0%

2 ended early

Currently Active

5

trials recruiting

Total Trials

12

all time

Status Distribution
Active(6)
Completed(3)
Terminated(2)
Other(1)

Detailed Status

Recruiting5
Completed3
Terminated2
unknown1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
5
Success Rate
60.0%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (14.3%)
Phase 23 (42.9%)
N/A3 (42.9%)

Trials by Status

unknown18%
recruiting542%
not_yet_recruiting18%
terminated217%
completed325%

Recent Activity

5 active trials
Showing 5 of 12
recruiting

Determining Individualized Cancer Therapy in Pancreatic Cancer

NCT05914987
not_yet_recruitingphase_1

Sequential FOLFOX-HAIC-TACE Plus Sintilimab-Bevacizumab Neoadjuvant Therapy Versus Direct Resection in Resectable High-Risk Recurrence Hepatocellular Carcinoma

NCT07522411
recruitingphase_2

Carbon Ion Radiotherapy for Locally Advanced Lung Cancer in Elderly Patients

NCT06311981
recruitingphase_2

Phase II Study of Serplulimab Combined with First-Line Targeted Therapy, Chemotherapy, and Radiation in Advanced Colorectal Cancer

NCT06521866
recruiting

A Single-cell Approach to Identify Biomarkers of Pulmonary Toxicity for Immune Checkpoint Blockade

NCT04807127
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT05914987

Determining Individualized Cancer Therapy in Pancreatic Cancer

Recruiting
NCT07522411Phase 1

Sequential FOLFOX-HAIC-TACE Plus Sintilimab-Bevacizumab Neoadjuvant Therapy Versus Direct Resection in Resectable High-Risk Recurrence Hepatocellular Carcinoma

Not Yet Recruiting
NCT06311981Phase 2

Carbon Ion Radiotherapy for Locally Advanced Lung Cancer in Elderly Patients

Recruiting
NCT06521866Phase 2

Phase II Study of Serplulimab Combined with First-Line Targeted Therapy, Chemotherapy, and Radiation in Advanced Colorectal Cancer

Recruiting
NCT04807127

A Single-cell Approach to Identify Biomarkers of Pulmonary Toxicity for Immune Checkpoint Blockade

Recruiting
NCT06249750Phase 2

Clinical Application of Near-infrared Whole Body Heat Shock Multimodal Technique in Treatment of Castration-resistant Prostate Cancer

Recruiting
NCT05535998

TACE-HAIC Combined With TKIs and Immunotherapy Versus TACE Alone for Hepatocellular Carcinoma With PVTT

Completed
NCT05177666

a Prospective Registration Study for Patients With Advanced Refractory Solid Tumors

Unknown
NCT02132845Not Applicable

Next Generation Sequence Target-Directed Therapy in Treating Patients With Cancer

Completed
NCT02745691

Psychometric Properties of the EORTC QLQ-LC29

Completed
NCT02132884Not Applicable

Genetic Sequencing-Informed Targeted Therapy in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer

Terminated
NCT02566421Not Applicable

Genomic Sequencing in Determining Treatment in Patients With Metastatic Cancer or Cancer That Cannot Be Removed by Surgery

Terminated

All 12 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
12